article thumbnail

Orna, a circular RNA specialist, acquires a buzzy startup

BioPharma Drive: Drug Pricing

After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.

RNA 112
article thumbnail

Roundtable: Panellists discuss the future RNA pipeline

Drug Discovery World

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RNA that doesn't age

Science Daily: Pharmacology News

Certain RNA molecules in the nerve cells in the brain last a life time without being renewed. RNAs are generally short-lived molecules that are constantly reconstructed to adjust to environmental conditions. Neuroscientists have now demonstrated that this.

RNA 123
article thumbnail

Exclusive roundtable on the delivery of RNA therapeutics

Drug Discovery World

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 130
article thumbnail

Roundtable: Discover how Covid-19 has influenced RNA research

Drug Discovery World

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 130
article thumbnail

Théa acquires ProQR’s RNA ophthalmic assets

Drug Discovery World

Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital amaurosis 10 due to the c.2991+1655A>G The post Théa acquires ProQR’s RNA ophthalmic assets appeared first on Drug Discovery World (DDW). 2991+1655A>G mutation (p.Cys998X) in the CEP290 gene.

RNA 130
article thumbnail

What are the challenges in the delivery of RNA therapeutics?

Drug Discovery World

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 130